Anti-vascular endothelial growth factor (anti-VEGF) injections have revolutionised vision for patients with macular degeneration or diabetic macular oedema. However, the choice of anti-VEGF is controversial. Two drugs licensed for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A third drug, bevacizumab (Avastin), is only licensed for colorectal cancer, and therefore, use in the eye is 'off label'. 1 Yet, all three are effective. Independently supported randomised controlled trials, 2, 3 and systematic reviews were unable to find a significant difference in safety or efficacy. 4, 5 The cost difference is significant however. Prices, according to the British National Formulary (BNF), are: ranibizumab; £742 per single injection vial, aflibercept; £816 per single injection vial; bevacizumab £242.66 per vial, but in practice each bevacizumab vial is divided into 20 injections, giving a price of £12.13 per injection. 6 In each case, these costs are multiplied many times over, because patients require repeated injections.
Given the current government's cost-cutting ambitions, 7 we hypothesised the majority of injections would use the less expensive drug, bevacizumab. We therefore performed a freedom of information (FOI) request to all UK NHS ophthalmological units for the number of ranibizumab, aflibercept, and bevacizumab injections prescribed during January 2015 (Table 1 and Figure 1) .
These results indicate the anti-VEGF injection cost to the NHS. Contrary to the hypothesis, the vast majority (97%) were with the more expensive drugs ranibizumab and aflibercept. If all injections used divided bevacizumab, the estimated cost would be £607 749 (£729 500 incl. VAT) saving the NHS £449 196 354 (£539 035 492 incl. VAT) per year. With 5% unaccounted for, savings may be greater. These figures assume: first, that procedural costs are the same. Second, that the frequency of injections would remain the same if solely using bevacizumab. (In fact, both aflibercept and bevacizumab have longer pharmacokinetic profiles, 8, 9 which should result in clinic visit rate reduction.) Third, that the injection rate for January 2015 is representative of every month.
The number of new patients, repeat injections, and cost are likely to escalate with an aging population. Popular belief in 2007 was antiVEGFs would 'cure' macular oedema. 10 However, clinical experience has shown that continued maintenance injections are required to prevent relapse. 11 We are only able to publish BNF prices. Confidential arrangements exist between companies and individual trusts, where drug price is negotiated in 'Patient Access Schemes', and we are not allowed to expose the true cost. Nevertheless, the evidence indicates a significant saving of using bevacizumab where appropriate. 12 So why not a switch towards using bevacizumab?
The answer is simple-it remains unlicensed, and the prescription of 'off label' drugs is not encouraged by the General Medical Council (GMC), whose guidelines state: 'Prescribing unlicensed medicines may be necessary where:
There is no suitably licensed medicine that will meet the patient's need…/Or where a suitably licensed medicine that would meet the patient's need is not available'.
We are not making the argument that licensing is unnecessary. Licensing prevents companies marketing drugs without evidence of a drug's safety post 'thalidomide era'. 13 This is regulated in the UK by the Medicines and Healthcare products Regulatory Authority (MHRA). 'Off label', for example, vials could be divided in the clinic: in a non-regulated environment, there is greater chance of infection, contamination, or incorrect dosage. 14 However, for anti-VEGF treatments, the situation is unusual. Arms of the same company produce bevacizumab and ranibizumab. Genentech (San Francisco, CA, USA), a subsidiary of Roche (Basel, Switzerland), markets ranibizumab in the USA and bevacizumab worldwide. Novartis (Basel, Switzerland), a major shareholder in Roche, markets ranibizumab outside the USA. There is no financial incentive for a company producing one drug licensed for macular oedema to license another cheaper drug it already produces.
The ability to change practice rests with advisors and those with the purchasing power. Further, GMC guidance states that clinicians must provide effective treatments based on the best available evidence, and must make good use of resources. A core remit of the National Institute for Health and Care Excellence (NICE) is to ensure NHS treatments are cost effective. The Royal College of Ophthalmologists stated:
'There is clear evidence that, despite the lack of a licence, Avastin is a safe and effective drug for the treatment of neovascular AMD. The College would therefore welcome an urgent review of this issue by the United Kingdom Health Regulatory Bodies to consider how this unusual situation can be remedied'. 15 In February 2015, 120 leaders of clinical commissioning groups wrote to the Health Secretary. The reply was negative:
'It would not only be unlawful but also against the wider public interest if ministers were to attempt to set aside that licensing system in order purely to cut costs'. 16 So how can we retain the benefits of the licensing system, but still ensure the most cost-effective drugs are licensed? One possible solution could be for NICE/MHRA to initiate licensing themselves, thus preserving quality control of bevacizumab preparation, while saving hundreds of millions of pounds of NHS budget.
We believe this is of public interest, for money saved could help many other patients. A paediatric intensive care bed costs £2000/night. The savings could fund 725 beds annually (currently just 431 of these beds exist in England), 17 or trastuzumab (Herceptin) for 4945 breast cancer patients, 18 or funding for all 53 childrens' hospices in the UK. Naomi House and Jacksplace in the South of England look after 363 children, costing £7 million per year, but only receive 10% of this from NHS England. 19 What is the practice elsewhere? In the USA, a marketdriven healthcare system, bevacizumab is the most popular anti-VEGF. 20 In Holland, bevacizumab is approved as first-line treatment for AMD, and a randomised trial to compare bevacizumab with ranibizumab for diabetic macular oedema is underway. 21 In Italy, Roche/Novartis were fined 180 million euros for trying to 'channel demand toward the much more expensive drug Lucentis, through an artificial distinction between the two products'. 22 To conclude, UK regulation has resulted in an unnecessarily expensive choice of anti-VEGF treatment, despite good evidence of safety, efficacy, cost savings, and support from the respected professional bodies for the use of bevacizumab, despite repeated requests to the Government.
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